Proudly backed by the VitaDAO community, the team at @Cyclarity recently presented some exciting news during #ARDD2026.
Their Phase 1a trials demonstrated that the therapy is well tolerated while successfully promoting the dose-dependent excretion of 7KC. Building on this momentum, the exact same 7KC target is now being evaluated for a second indication that extends well beyond atherosclerosis. Specifically, researchers discovered that combining UDP-003 with an existing FDA-approved agent significantly reduced liver fat accumulation in vivo, establishing a promising path toward addressing MASH.
You can explore the full scientific details and data by reading the abstract here: http://agingpharma.org/files/ARDD2026_Poster_Abstracts.pdf
Their Phase 1a trials demonstrated that the therapy is well tolerated while successfully promoting the dose-dependent excretion of 7KC. Building on this momentum, the exact same 7KC target is now being evaluated for a second indication that extends well beyond atherosclerosis. Specifically, researchers discovered that combining UDP-003 with an existing FDA-approved agent significantly reduced liver fat accumulation in vivo, establishing a promising path toward addressing MASH.
You can explore the full scientific details and data by reading the abstract here: http://agingpharma.org/files/ARDD2026_Poster_Abstracts.pdf